Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Executive Summary

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

You may also be interested in...



Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption

Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO

When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.

Biogen Bets Big To Bag Sage Depression And Tremor Drugs

Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel